Authors
Latest:
Dr. Zagaja on Major Benefit With ProstatectomyGregory Zagaja, MD, professor of Surgery, director of the Prostate Cancer Center at the University of Chicago Medicine, discusses the benefits of radical prostatectomy for patients with prostate cancer. Zagaja shared this insight during an interview at the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.
Latest:
Dr Nowakowski on the Significance of the TakeAim Lymphoma Trial in PCNSLGrzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.
Latest:
Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND StudyExpert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Dr. Argiles Discusses the Role of Immunotherapy in CRCGuillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses the role of immunotherapy in colorectal cancer.
Latest:
Garcia-Manero on MDS Treatment Updates With Luspatercept and BeyondDr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.
Latest:
Dr. Visani on Tosedostat and Cytarbine in Elderly Patients With AMLGuiseppe Visani, MD, director, Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy, discusses a phase II study examining the efficacy of tosedostat plus low-dose cytarabine in elderly patients with acute myeloid leukemia.
Latest:
Dr. Manji on Lack of Actionable Targets in Patients with Colorectal CancerGulam A. Manji, MD, PhD, discusses the importance of discovering other actionable targets for patients with colorectal cancer.
Latest:
Dr. von Minckwitz on Lessons Learned From Neoadjuvant Trials in Breast CancerGunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.
Latest:
Dr. von Minckwitz on the Safety Profile of the APHINITY Trial for HER2+ Breast CancerGunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the safety profile of the phase III APHINITY trial for patients with HER2-positive breast cancer.
Latest:
Dr Sonpavde on the Implications of the NIAGARA Trial Regimen in Bladder CancerGuru P. Sonpavde, MD, discusses the implications of treatment with the NIAGARA trial regimen in cisplatin-eligible muscle-invasive bladder cancer.
Latest:
Dr Sonpavde on an Exploratory Analysis of CheckMate 901 in Metastatic Urothelial CancerGuru P. Sonpavde, MD, discusses topline data from an exploratory analysis of CheckMate 901 in metastatic urothelial cancer.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter ValidationRapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Latest:
Dr. Jerusalem on Trastuzumab Deruxtecan in HER2+ Breast CancerGuy Jerusalem, MD, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.
Latest:
Dr. Young on the Challenges of Using Anticoagulants in Children With CancerGuy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.
Latest:
Gyorgy Petrovics on Frequency of BRCA Mutations in African American Prostate Cancer PatientsGyorgy Petrovics, PhD, associate director, Center for Prostate Disease Research (CPDR), research associate professor in the department of surgery at the Uniformed Services University of the Health Sciences (USUHS), discusses BRCA1 and BRCA2 mutations in African American prostate cancer patients.
Latest:
Dr. D'Souza on Screening for HPV-Related CancersGypsyamber D'Souza, PhD, MPH, MS, an associate professor of epidemiology at Johns Hopkins University, comments on screening for HPV-related cancers.
Latest:
Final Thoughts on Effective Therapy and Financial ToxicityExperts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.
Latest:
PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck RadiationA feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.
Latest:
Dr. Yimer on Long-Term Proteasome Inhibition in Newly Diagnosed MyelomaHabte A. Yimer, MD, of Texas Oncology, discusses a real-world study evaluating the long-term use of proteasome inhibition in patients with multiple myeloma, and transitioning from bortezomib (Velcade) to ixazomib (Ninlaro).
Latest:
Dr In on the Importance of Early Cancer Prevention Strategies in Gastric CancerHaejin In, MD, MPH, MBA, FACS, FSSO, discusses the importance of identifying individuals at high risk for developing gastric cancer.
Latest:
Dr. Kennecke on Available Treatments for GEP-NETsHagen F. Kennecke, MD, MHA, FRCPC, discusses the treatments available for patients with advanced gastroenteropancreatic neuroendocrine tumors.
Latest:
Advances in Ph+ ALL: Evolving Therapies and Future StrategiesHagop M. Kantarjian, MD, and Bijal D. Shah, MD, MS, delve into upcoming strategies for handling Philadelphia-chromosome positive acute lymphoblastic leukemia, considering recent breakthroughs.
Latest:
Dr. Cheng Discusses RICTOR Amplification in Lung CancerHaiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Care, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.
Latest:
Dr. Choy Discusses Therapy for Oligometastatic Lung CancerHak Choy, MD, Nancy B. & Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research, Department of Radiation Oncology, UT Southwestern Medical Center, discuses therapy for patients with oligometastatic lung cancer.
Latest:
Dr. Moore on the Use of Preventive Anastrozole Versus Tamoxifen in DCISHalle Moore, MD, discusses the use of preventive anastrozole versus tamoxifen in ductal carcinoma in situ.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Experts Give Advice on How to Plan a Successful Lung Cancer Screening ProgramScreening high-risk individuals for lung cancer with low-dose tomography is an effective and recommended approach for reducing mortality from the condition. That said, planning a lung cancer screening program can be challenging, as a successful program requires strategic multidisciplinary.
Latest:
Paving the Way to Modern Cancer TherapyWhen George P. Canellos, MD, first joined the field of oncology in the 1960s, many of his peers thought he was making huge mistake.
